Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS) and Summit Therapeutics (SMMT)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hims & Hers Health (HIMS – Research Report) and Summit Therapeutics (SMMT – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hims & Hers Health (HIMS)
TD Cowen analyst Jonna Kim maintained a Hold rating on Hims & Hers Health today and set a price target of $17.00. The company’s shares closed last Monday at $15.51, close to its 52-week low of $11.20.
According to TipRanks.com, Kim is a 4-star analyst with an average return of
Hims & Hers Health has an analyst consensus of Hold, with a price target consensus of $30.23, representing a 91.4% upside. In a report released today, TipRanks – OpenAI also downgraded the stock to Hold with a $16.50 price target.
See today’s best-performing stocks on TipRanks >>
Summit Therapeutics (SMMT)
In a report released today, Mitchell Kapoor from H.C. Wainwright maintained a Buy rating on Summit Therapeutics, with a price target of $30.00. The company’s shares closed last Monday at $16.09.
According to TipRanks.com, Kapoor is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Summit Therapeutics with a $31.17 average price target, implying a 97.9% upside from current levels. In a report released today, TipRanks – Google also upgraded the stock to Buy with a $18.00 price target.
